enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN) Stock Price, Analysis & Data
| Bid | 1.29 |
| Market Cap | 116.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -126.85M |
| Beta | -0.28 |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.23 |
| P/B (ttm) | 0.46 |
| P/S (ttm) | n/a |
| Earnings Date | Sep 14, 2026 |
| Ask | 2.25 |
| Volume | 959,158 |
| Avg. Volume (20D) | 1,148,869 |
| Open | 1.83 |
| Previous Close | 1.82 |
| Day's Range | 1.73 - 1.83 |
| 52-Week Range | 1.40 - 12.25 |
| Analyst | n/a |
| Price Target | 4 (129.89%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings In...
Financial Performance
In 2025, enGene Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -117.3M, an increase of 112.73%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for ENGN stock is "null". The 12-month stock price forecast is 4, which is upside of 129.89% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
